부산대학교 도서관

Fundamental and clinical studies of tazobactam/piperacillin (TAZ/PIPC), a newly developed β-lactamase inhibitor combined with piperacillin (PIPC), were performed, and the following results were obtained.In the fundamental study, concentrations of tazobactam (TAZ) and PIPC in the serum, female genital organs and retroperitoneal exudate were examined after the intravenous infusion of TAZ/PIPC. When 2.5g of TAZ/PIPC was administered by one-shot i. v. injection, the peripheral blood concentrations of TAZ and PIPC were 17.2 to 28.14μg/ml and 81.26 to 137.5μg/ml, respectively, at 45 to 55 minutes after administration. In these cases, TAZ and PIPC penetrated into the female genital organs at levels 10 to 120% of those in the peripheral blood.Peripheral blood concentrations of TAZ and PIPC were 45.32, μg/ml and 196.3 μg/ml, respectively, at the termination of drip infusion of TAZ/PIPC at 2.5g over a period of 60 minutes, and gradually decreased thereafter. Concentrations of TAZ and PIPC in retroperitoneal exudate reached their maximum levels, 10.95μg/ml and 56.88 μg/ml, respectively, at 60 minutes after drip infusion of 2.5 g. In a clinical trial, TAZ/PIPC was administered to 5 patients with obstetrical and gynecological infections such as pyometra, parametritis and pelvic peritonitis. Clinical efficacy was good in 4 and poor in 1. Bacteriologically, 10 organisms were isolated from 5 patients, and the eradication rate was 60.0%.No side effects were observed, but a transient elevation of GPT was observed in 1 case.